[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ras-g12d-mutated-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ras-g12d-mutated-nsclc":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100528549","phase-1-study-of-rason-inhibitors-in-patients-with-advanced-ras-mutated-nsclc-100528549",false,"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)","Inclusion criteria:\n\nAll Patients (unless otherwise noted):\n\n* ≥ 18 years of age\n* ECOG PS is 0 to 1\n* Adequate organ function as outlined by the study\n* Received prior standard therapy appropriate for tumor type and stage\n* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)\n* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)\n* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)\n\nExclusion criteria:\n\nAll Patients:\n\n* Primary central nervous system (CNS) tumors\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\n* Major surgery \\\u003C 28 days of first dose\n* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids\n\nOther inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},616,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.\n\nThe first four subprotocols include the following:\n\nSubprotocol A: RMC-6291 +\u002F- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +\u002F- RMC-6236 + SOC Subprotocol D: RMC-9805",[27,28,29,30,31],"Non-Small Cell Lung Cancer, NSCLC","KRAS, NRAS, HRAS-mutated NSCLC","KRAS G12C-mutated Solid Tumors, Lung Cancer","Lung Cancer Stage IV, Advanced Solid Tumor, Cancer","RAS G12D-mutated NSCLC",[33,34,35,36,37,38,39,40,41,42],"NSCLC","KRAS G12C","RAS Mutation","KRAS G12X","Non-Small Cell Lung Cancer","Lung Cancer","Lung Cancer Stage IV","Advanced Solid Tumor","Cancer","RAS G12D","RECRUITING","2026-06-25",{"date":46,"type":47},"2026-06-30","ACTUAL",{"date":49,"type":47},"2024-01-18",{"date":51,"type":20},"2028-12",{"name":53,"class":54},"Revolution Medicines, Inc.","INDUSTRY",93]